UR Medicine, RRH take part in trial for new Pfizer vaccine targeted at variant

In a release Monday, both healthcare systems announced it joined two phase 3 clinical trials to test Pfizer's new BNT162b2SA vaccine, which mimics the genetic code of the South African variant. The vaccine will be tested as a booster and as a stand-alone vaccine.